Streetbeat News

Regulatory

INTS

Intensity Therapeutics presented safety, tolerability, and efficacy data from its ongoing Phase 1/2 trial of INT230-6 in relapsed, refractory, and metastatic sarcomas at the Connective Tissue Oncology Society 2023 Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 11:48 am

TRVI

Trevi Therapeutics has initiated its Phase 2A RIVER trial of Haduvio in refractory chronic cough patients. The topline data from this trial is expected to be released in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 11:46 am

ACXP

Acurx Pharmaceuticals announced top-line results from Phase 2 trials of Ibezapolstat, showing a 96% clinical cure rate in patients with C. difficile infection. The drug was well tolerated with no serious adverse events reported. Further analyses are forthcoming, and preparations are underway for an End-of-Phase 2 FDA meeting and advancement to Phase 3. Despite the positive results, Acurx's shares experienced a selloff.

Portfolio Pulse from Charles Gross

November 02, 2023 | 11:45 am

ACXP

Acurx Pharmaceuticals has announced the efficacy results from the Phase 2 trial of Ibezapolstat for C. Difficile infection, with a 96% clinical cure rate in patients after 10 days of oral treatment. The trial met its primary objective of assessing the primary efficacy endpoint.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 11:44 am

CMP

Compass Minerals has announced the suspension of further investment in its planned lithium project until it has clarity on the evolving regulatory climate in Utah.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 11:29 am

SUPN

Supernus Pharmaceuticals has announced that the US FDA has acknowledged the resubmission of the New Drug Application (NDA) for the continuous treatment of motor fluctuations in Parkinson's disease.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 11:27 am

VGK

The Eurozone Manufacturing Purchasing Managers' Index (PMI) for October was reported at 43.1, lower than the estimated 43.4.

Portfolio Pulse from Charles Gross

November 02, 2023 | 9:05 am

VGK

The Eurozone Manufacturing Purchasing Managers Index (PMI) for October is reported at 43.1, slightly above the estimated 43.0 but below the prior figure of 43.4.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 9:04 am

VGK

The Manufacturing Purchasing Managers' Index (PMI) for the Eurozone in October was reported at 43.1, significantly higher than the estimated 3.4.

Portfolio Pulse from Charles Gross

November 02, 2023 | 9:03 am

EWG

Germany's Manufacturing Purchasing Managers Index (PMI) for October was reported at 40.8, slightly above the estimated 40.7 and significantly higher than the previous month's 39.6.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 8:55 am